Sipai Health Technology Co (FRA:AX1) 5-Year EBITDA Growth Rate: 46.20% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX1 Sipai Health Technology Co Ltd FRA:AX1
64 GF Score
Price €0.14
GF Value €0.22
! 5 Warning Signs
View Full Analysis

What is Sipai Health Technology Co 5-Year EBITDA Growth Rate?

Sipai Health Technology Co FRA:AX1 -2.80% 64 5-Year EBITDA Growth Rate is 46.20% as of Dec. 2025. GuruFocus rates FRA:AX1 with a GF Score™ of 64/100 and a GF Value™ of €0.22. The stock has 5 warning signs investors should review.

Sipai Health Technology Co's EBITDA per Share for the six months ended in Dec. 2025 was €-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 75.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 46.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sipai Health Technology Co was 75.90% per year. The lowest was -151.50% per year. And the median was 48.20% per year.


Sipai Health Technology Co  (FRA:AX1) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Sipai Health Technology Co 5-Year EBITDA Growth Rate Related Terms


FRA:AX1 vs MCK, COR, CAH: 5-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, Sipai Health Technology Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sipai Health Technology Co 5-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sipai Health Technology Co's 5-Year EBITDA Growth Rate falls into.


FRA:AX1
64GF Score
Sipai Health Technology Co Ltd FRA:AX1
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sipai Health Technology Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 46.20% mean?
Sipai Health Technology Co (FRA:AX1) has a 5-Year EBITDA Growth Rate of 46.20% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Sipai Health Technology Co and its competitors.
Is Sipai Health Technology Co's 5-Year EBITDA Growth Rate too high?
Sipai Health Technology Co's current 5-Year EBITDA Growth Rate is 46.20%. Overall, Sipai Health Technology Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's 5-Year EBITDA Growth Rate compare to MCK and COR?
Sipai Health Technology Co's 5-Year EBITDA Growth Rate of 46.20% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Distribution company?
A good 5-Year EBITDA Growth Rate depends on the Medical Distribution industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Sipai Health Technology Co and its competitors. Sipai Health Technology Co's current 5-Year EBITDA Growth Rate is 46.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Sipai Health Technology Co (FRA:AX1) has a current 5-Year EBITDA Growth Rate of 46.20%. The stock's GF Value™ is €0.22, compared to a current price of €0.14 — trading 36.8% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 46.20%. Sipai Health Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sipai Health Technology Co (FRA:AX1), the current 5-Year EBITDA Growth Rate is 46.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sipai Health Technology Co (FRA:AX1) Overvalued in 2026?

Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued. The current stock price of €0.14 is trading 36.8% below its estimated GF Value™ of €0.22.

Key valuation signals for FRA:AX1:

  • 5-Year EBITDA Growth Rate: 46.20%
  • GF Value™: €0.22 vs. price of €0.14 (36.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:AX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sipai Health Technology Co Business Description

Other Exchanges 00314:Hong Kong
Address 128 Tianmu West Road, 1603-1605A, 16th Floor, Tower 1, Kerry Enterprise Center, Jing\'an District, Shanghai, CHN
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
64GF Score

Get the complete analysis for FRA:AX1

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.22
GF Value